Omega-6 Fatty Acids Analysis Service

Omega-6 (n-6) fatty acids are the substrate pool for a large family of lipid mediators, and their concentrations, ratios, and oxidation products are used across inflammation, cardiovascular, metabolic, and nutrition research. We quantify the intact n-6 series together with conjugated linoleic acid isomers and 20+ LA- and AA-derived oxylipins. Because free and esterified pools answer different questions, chemical form, reporting basis, and analytical route are set before preparation.

What we analyze: LA, GLA, DGLA, AA, adrenic acid, osbond acid, CLA isomers, and 20+ n-6 oxylipins including HODE, EpOME, DiHOME, HETE, EET, prostanoid, and leukotriene species

Technology: GC-FID and GC-MS as fatty acid methyl esters, or targeted LC-MS/MS with isotope-labeled internal standards

Reporting options: Percentage of total fatty acids, mass fraction, absolute concentration, molar amount, defined sums, and specified n-6/n-3 or AA/DGLA ratios

Request Analysis

Submit Your Request Now

×

Our services have earned the trust of companies, schools, and organizations globally, and we remain dedicated to maintaining that trust.

Boston University
University at Buffalo
UMass Medical School
Hawaii Pacific University
Medizinische Fakultät
Louisiana State University
NYU Langone
Nature's Fynd
Dietary supplement manufacturer
  • Service We Provide
  • Omega-6 Panel
  • Advantages
  • Workflow
  • Results and Data Analysis
  • Sample Requirements
  • FAQ

What Are Omega-6 Fatty Acids and Why Quantify Them?

Linoleic acid is an essential dietary fatty acid, and the n-6 series extends from it through desaturation and elongation to arachidonic acid, the principal substrate for prostanoid, leukotriene, and epoxygenase signaling. Individual n-6 species therefore carry two kinds of information: they describe dietary intake and membrane composition, and they set the size of the precursor pool feeding mediator synthesis. This service measures the intact n-6 series and its oxidation products in one project, against a panel, chemical form, and reporting basis fixed before analysis.

Omega-6 Fatty Acid Analysis Services in Creative Proteomics

The routes below address different parts of the same n-6 question, from intact precursor profiling through isomer-level resolution to metabolite-level measurement, and can be combined within one study design.

n-6 Precursor Fatty Acid Profiling

Quantify LA, GLA, DGLA, AA, adrenic acid, and osbond acid in plasma, tissue, cells, oils, dairy, and formulated products by GC-FID, GC-MS, or LC-MS/MS. Results are reported as percentage of total fatty acids, mass fraction, or concentration, with the denominator stated per sample.

Free versus Total n-6 Fractionation

The unesterified n-6 pool and the total pool released by hydrolysis are measured as separate workflows. Free and total values are not interchangeable, so they are never merged into a single figure without an explicit note.

LA- and AA-Derived Oxylipin Panel

Targeted LC-MS/MS quantification of 20+ oxygenated n-6 metabolites, including 9-HODE, 13-HODE, the EpOME and DiHOME pairs, the 5-, 12-, 15-, and 20-HETE series, 15-HETrE, EETs, and selected prostanoids and leukotrienes. Isotope-labeled internal standards correct recovery and matrix effects per analyte.

Conjugated Linoleic Acid Isomer Analysis

Resolve c9,t11-CLA and t10,c12-CLA alongside the broader C18:2 positional and geometric isomer distribution on a polar capillary column, using low-temperature methylation that prevents cis-to-trans conversion. Applied to milk fat, ruminant tissue, and CLA-containing supplements.

Defined Sums and Pathway Ratios

AA/DGLA, LA/AA, adrenic/AA, n-6/n-3, and LA-branch versus AA-branch oxylipin ratios are calculated only when both terms are measured within one workflow on a consistent basis. The report lists the contributing species and the calculation basis for each metric.

Detectable Omega-6 Fatty Acids and n-6 Oxylipin Panels

The omega-6 fatty acid family spans a small number of intact precursor species and a much larger set of oxidation products. The tables below list the analytes routinely covered; the final panel is confirmed against the matrix, expected abundance, and reference-standard availability before testing begins.

  • Precursor Fatty Acids
  • Oxylipin Panels
  • Sums & Ratios

n-6 Precursor Fatty Acids and Their Isomers

The intact n-6 series is quantified as a set, so that each measured species can be placed at a defined position in the desaturation and elongation sequence rather than reported in isolation.

Common Name Abbreviation Lipid Shorthand Position in the n-6 Pathway
Linoleic acid LA 18:2 n-6 Dietary essential precursor and the predominant n-6 species in most matrices
Gamma-linolenic acid GLA 18:3 n-6 Delta-6 desaturation product of LA; used to assess desaturase activity
Eicosadienoic acid EDA 20:2 n-6 Elongation product of LA on the competing elongation branch
Dihomo-gamma-linolenic acid DGLA 20:3 n-6 Substrate for 1-series prostanoid synthesis and the immediate precursor of AA
Arachidonic acid AA (ARA) 20:4 n-6 Principal substrate for prostanoid, leukotriene, and epoxygenase pathways
Adrenic acid AdA 22:4 n-6 Elongation product of AA; enriched in adrenal, neural, and renal tissue
Osbond acid — 22:5 n-6 Terminal n-6 elongation and desaturation product; elevated when n-3 availability is limited
Conjugated linoleic acid isomers CLA 18:2 conjugated Ruminant- and supplement-derived positional isomers, reported as c9,t11 and t10,c12 separately

Depending on the study question, the panel can be extended to the broader unsaturated fatty acid analysis series, to a defined polyunsaturated fatty acid analysis set, or to a full profile across all fatty acid classes.

LA- and AA-Derived Oxylipin Panels

Oxygenated n-6 metabolites are grouped by precursor and by enzymatic route, so that a change in one branch can be distinguished from a change in substrate availability. Where a route matters to the study design, the corresponding standalone panel is available.

Oxylipin Class Representative Analytes Precursor Principal Route
Hydroxyoctadecadienoic acids 9-HODE, 13-HODE, 9-oxoODE, 13-oxoODE LA 15-lipoxygenase and non-enzymatic oxidation
Epoxyoctadecenoic acids 9,10-EpOME, 12,13-EpOME LA Cytochrome P450 epoxygenase
Dihydroxyoctadecenoic acids 9,10-DiHOME, 12,13-DiHOME LA Soluble epoxide hydrolase acting on EpOMEs
Hydroxyeicosatrienoic acid 15-HETrE DGLA 15-lipoxygenase
Hydroxyeicosatetraenoic acids 5-HETE, 12-HETE, 15-HETE, 20-HETE AA Lipoxygenase and CYP450 omega-hydroxylation
Epoxyeicosatrienoic acids 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET AA Cytochrome P450 epoxygenase
Dihydroxyeicosatrienoic acids 11,12-DiHETrE, 14,15-DiHETrE AA Soluble epoxide hydrolase acting on EETs
Prostanoids PGE2, PGD2, PGF2alpha, TXB2 AA Cyclooxygenase-1 and cyclooxygenase-2
Leukotrienes LTB4, LTC4, LTE4 AA 5-lipoxygenase

Route-specific panels are available where a single enzymatic branch is the study endpoint: hydroxyeicosatetraenoic acid analysis for the LOX and omega-hydroxylation products, and epoxyeicosatrienoic acid analysis for the epoxygenase branch and its hydrolysis products.

Reported Sums, Ratios, and Pathway Indices

Sums and ratios are reported as defined metrics rather than as derived values of unknown composition. Every entry below states which species contribute and on what basis the calculation is made.

Metric Definition Calculation Basis
Total n-6 fatty acids Sum of all measured n-6 species in the panel Reported as percentage of total fatty acids, mass fraction, or concentration, with contributing species listed
n-6/n-3 ratio Summed n-6 species relative to summed n-3 species Both sums are measured in the same derivatization or extraction workflow and expressed on one basis
AA/DGLA ratio Arachidonic acid relative to dihomo-gamma-linolenic acid An index of delta-5 desaturase activity and of the balance between the two eicosanoid precursor pools
LA/AA ratio Linoleic acid relative to arachidonic acid Describes the relationship between the dietary precursor and its principal downstream substrate
Adrenic/AA ratio Adrenic acid relative to arachidonic acid An elongation index for tissues in which adrenic acid accumulates, such as adrenal gland and brain
EpOME/DiHOME ratio Summed epoxyoctadecenoic acids relative to their dihydroxy metabolites Widely used as an index of soluble epoxide hydrolase activity within the LA branch
LA-branch/AA-branch oxylipin ratio Summed octadecanoids relative to summed eicosanoids Describes the shift between the two oxidation branches of n-6 mediator synthesis

Why Choose Our Omega-6 Analysis Platform

  • Isomer-resolved quantification: A polar capillary GC column separates positional and geometric C18:2 isomers, including c9,t11- and t10,c12-CLA, which share the same nominal mass. Methylation runs at room temperature, so cis-to-trans conversion does not occur during derivatization.
  • Oxidation-controlled LA handling: LA predominates among polyunsaturated fatty acids in most matrices and oxidizes readily ex vivo. Extraction runs under nitrogen with antioxidant stabilization, and extracts are held in amber vials below minus 70 degrees Celsius, so HODE, EpOME, and DiHOME values describe the sample.
  • Ratios with a stated basis: Every ratio uses only analytes measured in one workflow on one basis. Contributing species and the denominator appear in the report, so a value can be compared with published data rather than only within the study.
  • Defined acceptance criteria: Calibration linearity of r-squared 0.995 or better, intra-day precision below 5 percent at mid and upper levels, and intra- and inter-day precision within 15 percent for low-abundance oxylipins, set per matrix during method planning.
  • Precursor and metabolite from one batch: The intact n-6 fatty acids and their oxidized products can be measured from a single extraction batch, so precursor and product data share sample identity, storage history, and reporting basis.
  • Matrices beyond plasma: Methods are validated for plasma, serum, whole blood, erythrocytes, tissue, cultured cells, oils, dairy, feeds, and formulated products. Each new matrix is evaluated for extraction recovery before the panel is fixed.
  • Limitations reported, not summarized away: Peak integration boundaries, internal-standard responses, observed matrix effects, and any qualified or excluded results are provided with the data.

Omega-6 Fatty Acid Analysis Workflow

Omega-6 fatty acid analysis workflow from feasibility review to reportingSix-step omega-6 analysis workflow: feasibility and study-design review, panel and method selection, matrix-specific sample preparation, instrumental analysis, data processing and QC review, and reporting with interpretation support.

The workflow is modular rather than fixed. An oil or dairy project rests mainly on representative sampling, FAME conversion, and column resolution; a plasma or tissue study rests more on collection consistency, storage history, hydrolysis choice, isotope labeling, and matrix effects. In both cases the pre-analytical chemistry and the reporting basis are settled before data generation starts.

Platforms Used for Omega-6 Fatty Acid Analysis

Agilent 7890A GC System

Agilent 7890A GC System (Figure from Agilent) — fatty acid methyl ester separation with flame ionization detection

SCIEX Triple Quad 6500+

SCIEX Triple Quad 6500+ (Figure from SCIEX) — scheduled MRM for intact n-6 fatty acids and their oxygenated metabolites

Method Specifications for Omega-6 Fatty Acid Analysis

Parameter Specification
Derivatization Fatty acid methyl esters with acetyl chloride in methanol for GC routes; intact fatty acids and oxylipins on LC-MS/MS require no derivatization
GC separation Polar capillary column with a cyanopropyl stationary phase, 17 to 20 minute programmed-temperature run, resolving positional and geometric C18:2 isomers
GC detection Flame ionization detection for relative composition; single quadrupole SIM where identification support is required
LC separation Reversed-phase C18 with gradient elution, separately optimized for intact fatty acids and for oxygenated metabolites
Ionization Electrospray ionization in negative ion mode for free fatty acids and oxylipins
Acquisition mode Scheduled multiple reaction monitoring with isotope-labeled internal standards assigned per analyte
Isomer resolution c9,t11- and t10,c12-CLA are resolved chromatographically; low-temperature methylation prevents cis-to-trans conversion during derivatization
Oxidation control Nitrogen-atmosphere extraction with antioxidant stabilization; amber vials below minus 70 degrees Celsius; HODE and EpOME monitored in blanks and QC samples of every batch
Calibration Stable isotope dilution with calibration linearity r-squared of 0.995 or better across the working range
Precision Intra-day coefficient of variation below 5 percent at mid and upper calibration levels; intra- and inter-day precision within 15 percent for low-abundance oxylipins
Reporting basis Percentage of total fatty acids, mass fraction, molar amount, or absolute concentration, with the denominator stated per sample

Where a single method must cover all fatty acid classes rather than the n-6 series alone, the workflow is aligned with our fatty acid profiling by GC-FID and GC-MS platform; the total-composition route follows the derivatization scheme described for fatty acid methyl ester analysis, so composition data and free-pool data can be placed side by side without changing the reporting basis.

Results and Data Analysis

Comprehensive Omega-6 Profiling Report

The core report organizes the intact n-6 fatty acids, the oxylipin panel, and the derived ratios in separate tables that share sample identifiers and units, together with the method notes needed to interpret them.

Key Features:

  • Species-level results for LA, GLA, DGLA, AA, adrenic acid, osbond acid, and CLA isomers, with the calibration curve and calculation basis for each
  • Oxylipin results grouped by precursor and enzymatic route, with isotope-labeled internal standard response recorded per analyte
  • A QC summary covering calibration performance, blank observations, internal-standard behavior, replicate agreement, and any qualified results
  • Method notes describing extraction, derivatization or hydrolysis, chromatographic conditions, and the reporting basis actually used

Raw instrument files can be discussed during project planning when they are required for archiving or independent review.

Representative GC-FID chromatogram of n-6 fatty acid methyl esters

Representative GC-FID separation of n-6 fatty acid methyl esters with LA, GLA, DGLA, AA, and adrenic acid annotated.

Representative n-6 oxylipin MRM panel and ratio comparison

Representative targeted LC-MS/MS oxylipin panel with LA-branch and AA-branch metabolites, shown with group-wise ratio comparison.

Ratio, Sum, and Pathway Report

Sums and ratios are reported as defined metrics with their composition stated, so that a value can be compared with previously published data and with earlier batches from the same study.

Key Features:

  • Total n-6, n-6/n-3, AA/DGLA, LA/AA, and adrenic/AA values with contributing species listed
  • EpOME/DiHOME and EET/DiHETrE values reported as indices of soluble epoxide hydrolase activity
  • LA-branch versus AA-branch oxylipin balance, with consistent denominators across all samples in a batch and any change in basis flagged explicitly

Group Comparison and Interpretation Support

Optional statistical and visual analysis is planned before data acquisition, so that group structure, replicate type, missing-value handling, and normalization are not decided after the results are visible.

Key Features:

  • Univariate group comparisons with fold change and adjusted significance where the design supports it
  • Profile plots, heat maps, and precursor-to-metabolite relationship plots
  • Pathway mapping of measured n-6 metabolites through desaturation, elongation, and oxidation routes
  • Editable tables in CSV or XLSX and report-ready figures in PNG or SVG format, with a PDF summary on request

Omega-6 desaturation, elongation, and oxidation pathway mapOmega-6 Desaturation, Elongation, and Oxidation Pathways: LA to GLA to DGLA to AA to adrenic acid by desaturation and elongation, with LA- and AA-derived oxidation branches through 15-LOX, CYP450, soluble epoxide hydrolase, cyclooxygenase, and 5-lipoxygenase.

Projects that extend into the wider oxidized lipid mediator landscape can be coordinated with oxylipin quantification and pathway profiling, which places the n-6 metabolites alongside their n-3 counterparts within one data structure.

What Omega-6 Fatty Acid Analysis Is Used For

The same panel supports projects that differ widely in matrix, endpoint, and required reporting basis. Designs that do not match the patterns below are adapted during feasibility review.

Inflammation and Lipid Mediator Research

Measure the LA and AA branches together with their precursor pool, so that a study can distinguish a change in substrate availability from a change in enzyme activity. DiHOME and HETE panels resolve the soluble epoxide hydrolase and lipoxygenase routes separately.

Cardiometabolic and Nutritional Studies

Use circulating and tissue n-6 species as biomarkers of dietary fat intake and as exposure variables in cohort and intervention designs. Reporting as percentage of total fatty acids allows comparison with published pooled analyses of LA and AA.

Dairy, Ruminant, and Supplement Characterization

Resolve c9,t11- from t10,c12-CLA and profile the wider C18:2 isomer distribution in milk fat, meat, and formulated supplements, where isomer identity rather than total CLA content determines the research question.

Food, Feed, and Oil Characterization

Verify n-6 composition and the LA-to-AA relationship in oils, feeds, and fortified products, and track process-driven or lot-to-lot changes in the measured profile across production batches.

Sample Requirements for Omega-6 Fatty Acid Analysis

Sample Type Collection and Handling Typical Starting Amount Planning Notes
Plasma or serum Collect with a documented anticoagulant protocol; separate promptly, aliquot, and store below minus 70 degrees Celsius 100 microliters (unesterified pool); 200 microliters or more for total fatty acids plus oxylipins Use one anticoagulant and one processing delay across all samples; record fasting state and storage duration
Whole blood or erythrocytes Wash and prepare erythrocytes consistently; snap-freeze the pellet and ship on dry ice 100 microliters of packed cells Erythrocyte n-6 composition reflects longer-term intake than plasma; state the fraction measured
Tissue Snap-freeze in liquid nitrogen immediately after dissection; store below minus 70 degrees Celsius 20 to 50 milligrams fresh weight Record wet weight, protein content, or another normalization variable, and keep it consistent across groups
Cultured cells or cell pellets Wash with cold buffer, remove supernatant completely, and flash-freeze 5 million cells or more Record cell count, protein content, and passage number; medium carryover changes the free fatty acid fraction
Oils and lipid ingredients Store sealed in amber glass, protected from light, heat, and headspace oxygen 100 microliters or more Provide the declared composition, antioxidant content, and expected concentration range where known
Dairy and ruminant products Collect a representative portion; keep chilled or frozen and protect from light 1 gram or more Fat content varies strongly within and between products, so homogenization and reporting basis must be defined in advance
Foods, feeds, and formulated products Provide a homogenized representative sample; state whether the sample is a dry powder, emulsion, or capsule fill 0.2 to 1 gram State the intended reporting basis, such as per mass of sample, per gram of fat, or per gram of total fatty acids

Amounts above are planning figures. Final quantities are confirmed once the target panel and analytical route are selected, because a low-abundance oxylipin panel, a broad fatty acid profile, and a repeat analysis do not have the same requirement. The FAQ below lists the information needed to begin a feasibility review.

Frequently Asked Questions About Omega-6 Fatty Acid Analysis

Should I request free or total omega-6 fatty acids?

The two pools answer different questions. Free fatty acids are the unesterified fraction present at collection. A total-fatty-acid workflow hydrolyzes the esterified fraction and therefore also captures fatty acids released from phospholipids, triglycerides, and cholesteryl esters. Published validated plasma assays measure free and total omega-3 and omega-6 fatty acids separately, but report the two in their own units; they are not interchangeable.

  • Choose the free pool when the question concerns circulating unesterified substrate or acute lipolytic release
  • Choose total fatty acids when the question concerns membrane composition, habitual intake, or tissue stores
  • Choose a defined fraction, such as plasma phospholipids, when the study protocol specifies it in advance

Can linoleic acid and arachidonic acid be quantified in the same run?

In most matrices, yes. LA and AA differ substantially in abundance, and in plasma the gap can exceed an order of magnitude, so the calibration range is set to cover both ends rather than centered on the mid-range. Where an individual species falls outside the calibrated range, the dilution or concentration step is documented and the result is flagged so that it is not read as a direct measurement.

How do you control linoleic acid oxidation during sample preparation?

LA predominates among polyunsaturated fatty acids in most matrices and is susceptible to ex vivo autoxidation, so HODE, EpOME, and DiHOME can form after collection rather than in the biological system. Extraction runs under nitrogen with antioxidant stabilization, samples are processed cold, and extracts are stored in amber vials below minus 70 degrees Celsius. Freeze-thaw cycles are avoided because they change measured oxylipin profiles.

Can c9,t11-CLA be separated from t10,c12-CLA?

Yes. CLA isomers share the same nominal mass and cannot be distinguished by MS alone, so separation is achieved chromatographically on a polar capillary column. The second requirement is chemical: raising fatty acids to 95 degrees Celsius during methylation promotes cis-to-trans isomerization and can generate conjugated isomers absent from the sample, so derivatization runs at room temperature. Reported precision for plasma fatty acid methyl esters is better than 10 percent coefficient of variation with this approach.

How is the n-6/n-3 ratio defined?

The ratio depends entirely on which species are summed and on the reporting basis, so it is meaningless without both. Reports list the species contributing to the numerator and denominator, the units, and whether the value is calculated on percentage composition, molar amount, or absolute concentration. Ratios calculated on different bases are not comparable to each other.

In pooled cohort analyses of omega-6 biomarkers, LA and AA are conventionally expressed as a percentage of total fatty acids, which is the basis used when results are intended for comparison with that literature.

Is this service for clinical diagnostic use?

No. This service is for research use only. It is not intended for clinical diagnostic procedures, patient management, or treatment decisions, and no result is reported as a clinical index. Clinical fatty acid profile testing and omega-3 or omega-6 index assays are performed by licensed clinical laboratories. If your study involves samples that may require clinical follow-up, indicate this during study design.

What information is needed for a quote?

Provide the matrix, species or product type, number of groups and replicates, total sample count, priority analytes, expected concentration range where known, free or total measurement preference, requested reporting units, available sample amount, and storage history. Mention any diet, treatment, processing step, or formulation component that could affect interpretation, along with the comparisons the data must support.

References

  1. Development and Validation of a LC-MS/MS-Based Assay for Quantification of Free and Total Omega 3 and 6 Fatty Acids from Human Plasma. Molecules (2019). https://doi.org/10.3390/molecules24020360
  2. Development of a Liquid Chromatography-Tandem Mass Spectrometry Method for Oxylipin Analysis and Its Application to Children's Plasma. Diagnostics (2025). https://doi.org/10.3390/diagnostics15151870
  3. Albiach-Delgado, A., Cascant-Vilaplana, M. M., Pinilla-Gonzalez, A., et al. "Assessment of dried blood micro-sampling methods for oxylipin analysis in newborn blood using UPLC-MS/MS." Analytica Chimica Acta (2025). https://doi.org/10.1016/j.aca.2025.344373
  4. A rapid GC-MS method for quantification of positional and geometric isomers of fatty acid methyl esters. Journal of Chromatography B (2012). https://doi.org/10.1016/j.jchromb.2012.04.015
  5. Dihomo-gamma-Linolenic Acid (20:3n-6): Metabolism, Derivatives, and Potential Significance in Chronic Inflammation. International Journal of Molecular Sciences (2023). https://doi.org/10.3390/ijms24032116
  6. Mercola, J., & D'Adamo, C. R. "Linoleic Acid: A Narrative Review of the Effects of Increased Intake in the Standard American Diet and Associations with Chronic Disease." Nutrients (2023). https://doi.org/10.3390/nu15143129
  7. Jamieson, K. L., Endo, T., Darwesh, A. M., et al. "Cytochrome P450-derived eicosanoids and heart function." Pharmacology & Therapeutics (2017). https://doi.org/10.1016/j.pharmthera.2017.05.005
  8. Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality: An Individual-Level Pooled Analysis of 30 Cohort Studies. Circulation (2019). https://doi.org/10.1161/CIRCULATIONAHA.118.038908
  9. Omega-6/omega-3 oxylipin imbalance and altered 15-LOX and sEH pathways in Fontan physiology. American Journal of Physiology-Heart and Circulatory Physiology (2026). https://doi.org/10.1152/ajpheart.00901.2025
  10. Tan, X., Ni, H., Li, Q., et al. "Systematic Profile of Oxylipins in Myocardial Infarction by Liquid Chromatography-Tandem Mass Spectrometry." Rapid Communications in Mass Spectrometry (2025). https://doi.org/10.1002/rcm.9999
* Our services can only be used for research purposes and Not for clinical use.

Online Inquiry

CONTACT US

  • USA
  • Tel: 1-631-275-3058 (USA)
  • Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
  • Email:
  • Fax: 1-631-614-7828
  • Germany
  • Address: 65830 Kriftel, Gutenbergstraße 5. Frankfurt am Main, Germany
Copyright © 2026 Creative Proteomics. All rights reserved.